Shots:

• The P-II trial evaluates sotigalimab + pembrolizumab in patients with advanced or metastatic melanoma. The combination induced broad innate & adaptive immune activation in local & distant tumors
• The results showed ORR (50% & 55%) at the RP2D of sotiga (10mg), DCR (67%), CR rate (17%), PR (33%) & SD (17%), clinical responses were seen in patients with PD-L1- tumors & with elevated LDH. The combination demonstrated an encouraging anti-tumor activity, upregulation of genes associated with APC & T cells, increase in T cell infiltration & clonality in both tumor sites
• The combination was well-tolerated, 6 patients experienced grade 3 immune-mediated AEs with no dose-limiting toxicities and no discontinuations or deaths

Ref: Globe Newswire | Image: Apexigen